.Pharmacolibrary.Drugs.ATC.R.R03BB07 .Pharmacolibrary.Drugs.ATC.R.R03BB07| name: | UmeclidiniumBromide |
| ATC code: | R03BB07 | route: | inhalation |
| n-compartments | 2 |
Umeclidinium bromide is a long-acting muscarinic antagonist (LAMA) used as a bronchodilator for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is administered as an inhalation powder and is approved for use in adults to improve airflow and reduce symptoms in COPD patients.
Reported PK parameters in healthy adult subjects following inhaled administration of umeclidinium bromide.
Mehta, R, et al., & Lipson, DA (2020). Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Clinical pharmacokinetics 59(1) 67–79. DOI:10.1007/s40262-019-00794-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/31321713
Yang, S, et al., & Peachey, G (2021). Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). Clinical pharmacokinetics 60(7) 887–896. DOI:10.1007/s40262-021-00988-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33598874
Church, A, et al., & Shah, P (2014). Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC pulmonary medicine 14 2–None. DOI:10.1186/1471-2466-14-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24393134